Fate Therapeutics Net Income From Continuing Ops Over Time
| FATE Stock | USD 1.19 0.02 1.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fate Therapeutics Performance and Fate Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Fate diversify its offerings? Factors like these will boost the valuation of Fate Therapeutics. Market participants price Fate higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fate Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.32) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Fate Therapeutics and related stocks such as Nkarta Inc, Alector, and Vor Biopharma Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKTX | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (21.1 M) | (91.4 M) | (86.1 M) | (113.8 M) | (122.3 M) | (108.8 M) | (97.9 M) | (102.8 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.5 M) | (52.2 M) | (105.4 M) | (190.2 M) | (36.3 M) | (133.3 M) | (141.4 M) | (119 M) | (107.1 M) | (112.5 M) |
| VOR | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (10.8 M) | (43.3 M) | (68.9 M) | (92.1 M) | (115.5 M) | (116.9 M) | (105.2 M) | (100 M) |
| SAVA | (2.6 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.6 M) | (6.3 M) | (32.4 M) | (76.2 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
| PRLD | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (27.6 M) | (56.9 M) | (111.7 M) | (115.4 M) | (117.4 M) | (127.2 M) | (114.5 M) | (120.2 M) |
| INO | (12.9 M) | (12.9 M) | (21.3 M) | (65 M) | (38.8 M) | (29.1 M) | (73.7 M) | (88.2 M) | (97 M) | (120.5 M) | (162.9 M) | (303.2 M) | (277.7 M) | (164.6 M) | (107.3 M) | (96.5 M) | (101.4 M) |
| PEPG | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (85 M) |
| MOLN | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (59.6 M) | (54 M) | (62.1 M) | (59 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (48.7 M) | (102.3 M) | (92.1 M) | (87.5 M) |
| CRBP | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (8.9 M) | (20 M) | (32.4 M) | (55.7 M) | (71.5 M) | (111.3 M) | (45.6 M) | (42.3 M) | (47.5 M) | (40.2 M) | (36.2 M) | (38 M) |
Fate Therapeutics and related stocks such as Nkarta Inc, Alector, and Vor Biopharma Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Fate Therapeutics | FATE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 12278 Scripps Summit |
| Exchange | NASDAQ Exchange |
USD 1.19
Check out Fate Therapeutics Performance and Fate Therapeutics Correlation. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Fate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.